Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-11-18

Clinical Trial Update: A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin [Phase 3]

View source ↗

Summary

A Phase 3 head-to-head trial comparing insulin degludec 200 U/mL with insulin glargine in adults with Type 2 diabetes requiring high-dose insulin, reporting eff…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lantus (insulin glargine)
  • Tresiba (insulin degludec)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2015-11-18